Publications searcher

The science produced by our scientists is very important. In 2022, 1,629 papers were published in scientific journals with a global impact factor of over 15,000 points.

Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.

PMID: 31610549
Journal: ANNALS OF INTERNAL MEDICINE
Year: 2019
Reference: Ann Intern Med. 2019 Nov 19;171(10):685-694. doi: 10.7326/M19-0291. Epub 2019 Oct 15.
Impact factor: 19.315
Publication type: Paper in international publication
Authors: Cuquet-Pedragosa, Jordi, Ortiz-Santamaria, Vera, Mauri-Plana, Montserrat, Sole, Cristina, Cortes-Hernandez, Josefina, Castro-Salomo, Antoni, Riera-Mestre, Antoni, Vidal, Xavier, Perez-Conesa, Mercedes, Ordi-Ros, Josep et al.
DOI: 10.7326/M19-0291

RNF43- and NOTCH1-Mutated Chemotherapy and Anti-EGFR-Refractory Colorectal Cancer: Should Clonality Guide Target Prioritization With Investigational Therapies?

PMID: 35100710
Journal: JCO precision oncology
Year: 2019
Reference: JCO Precis Oncol. 2019 Dec;3:1-3. doi: 10.1200/PO.19.00182.
Impact factor: 0
Publication type: Letter or abstract
Authors: Dienstmann, Rodrigo, Vivancos, Ana, Nuciforo, Paolo, Garralda, Elena, Aguilar, Susana, Santos, Cristina, Martini, Giulia, Argiles, Guillem, Azaro, Analia, Tabernero, Josep et al.
DOI: 10.1200/PO.19.00182

Robust one-pot synthesis of citrate-stabilized Au@CeO2 hybrid nanocrystals with different thickness and dimensionality

PMID: NOPMID0065
Journal: Applied Materials Today
Year: 2019
Reference: Applied Materials Today. 2019 Jun;15:445-52. doi:10.1016/j.apmt.2019.03.003
Impact factor: 8.013
Publication type: Paper in international publication
Authors: Piella, Jordi, Bastus, Neus G., Genc, Aziz, Arbiol, Jordi, Puntes, Victor, Patarroyo, Javier, Perez, Sara et al.
DOI: 10.1016/j.apmt.2019.03.003

Role of Immunofluorescence and Molecular Diagnosis in the Characterization of Primary Ciliary Dyskinesia.

PMID: 30850195
Journal: ARCHIVOS DE BRONCONEUMOLOGIA
Year: 2019
Reference: Arch Bronconeumol. 2019 Aug;55(8):439-441. doi: 10.1016/j.arbres.2019.01.021. Epub 2019 Mar 5.
Impact factor: 4.214
Publication type: Paper in national publication
Authors: Baz-Redon, Noelia, Rovira-Amigo, Sandra, Camats-Tarruella, Nuria, Fernandez-Cancio, Monica, Garrido-Pontnou, Marta, Antolin, Maria, Reula, Ana, Armengot-Carceller, Miguel, Carrascosa, Antonio, Moreno-Galdo, Antonio et al.
DOI: 10.1016/j.arbres.2019.01.021

Role of Magnetic Resonance Imaging and Cranial Ultrasonography in Congenital Cytomegalovirus Infection.

PMID: 31626048
Journal: PEDIATRIC INFECTIOUS DISEASE JOURNAL
Year: 2019
Reference: Pediatr Infect Dis J. 2019 Nov;38(11):1131-1137. doi: 10.1097/INF.0000000000002455.
Impact factor: 2.317
Publication type: Paper in international publication
Authors: Santos, Mar, Blazquez-Gamero, Daniel, Soriano-Ramos, Maria, Martinez de Aragon, Ana, Baquero-Artigao, Fernando, Frick, Marie Antoinette, Noguera-Julian, Antoni, Alonso-Ojembarrena, Almudena, Moliner Calderon, Elisenda, Rives Ferreiro, Maria Teresa et al.
DOI: 10.1097/INF.0000000000002455

Role of Nucleic Acid Amplification assays in monitoring treatment response in Chagas disease: Usefulness in clinical trials.

PMID: 31376368
Journal: ACTA TROPICA
Year: 2019
Reference: Acta Trop. 2019 Nov;199:105120. doi: 10.1016/j.actatropica.2019.105120. Epub 2019 Jul 31.
Impact factor: 2.629
Publication type: Review in international publication
Authors: Sulleiro, Elena, Munoz-Calderon, Arturo, Schijman, Alejandro G et al.
DOI: 10.1016/j.actatropica.2019.105120

Role of rivaroxaban in the prevention of atherosclerotic events.

PMID: 31269825
Journal: Expert Review of Clinical Pharmacology
Year: 2019
Reference: Expert Rev Clin Pharmacol. 2019 Aug;12(8):771-780. doi: 10.1080/17512433.2019.1637732. Epub 2019 Jul 9.
Impact factor: 2.776
Publication type: Paper in international publication
Authors: Bellmunt, Sergi, Cosin-Sales, Juan, Garcia-Moll, Xavier, Riera Mestre, Antoni, Almendro-Delia, Manuel, Hernandez, Jose Luis, Lozano, Francisco, Mazon, Pilar, Suarez Fernandez, Carmen, Sanmartin, Marcelo et al.
DOI: 10.1080/17512433.2019.1637732

Ruling Out Acute Coronary Syndromes: Troponin Is Essential, as Is Clinical Assessment.

PMID: 31416528
Journal: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Year: 2019
Reference: J Am Coll Cardiol. 2019 Aug 20;74(7):855-857. doi: 10.1016/j.jacc.2019.05.065.
Impact factor: 18.639
Publication type: Editorail in international publication
Authors: Cediel, German, Bardaji, Alfredo, Barrabes, Jose A et al.
DOI: 10.1016/j.jacc.2019.05.065

Ryanodine Receptor Glycation Favors Mitochondrial Damage in the Senescent Heart.

PMID: 30586718
Journal: CIRCULATION
Year: 2019
Reference: Circulation. 2019 Feb 12;139(7):949-964. doi: 10.1161/CIRCULATIONAHA.118.035869.
Impact factor: 23.054
Publication type: Paper in international publication
Authors: Garcia-Dorado, David, Ruiz-Meana, Marisol, Minguet, Marta, Bou-Teen, Diana, Miro-Casas, Elisabet, Castans, Celia, Castellano, Jose, Bonzon-Kulichenko, Elena, Igual, Alberto, Rodriguez-Lecoq, Rafael et al.
DOI: 10.1161/CIRCULATIONAHA.118.035869

Safe and Efficacious Use of 1-Month Triple Therapy in Patients with Atrial Fibrillation and High Bleeding Risk Undergoing PCI.

PMID: 31332653
Journal: CARDIOVASCULAR DRUGS AND THERAPY
Year: 2019
Reference: Cardiovasc Drugs Ther. 2019 Aug;33(4):425-433. doi: 10.1007/s10557-019-06889-7.
Impact factor: 4.181
Publication type: Paper in international publication
Authors: Sambola, Antonia, Bueno, Hector, Miranda, Berta, Hernandez, Adrian V, Limeres, Javier, Del Blanco, Bruno Garcia, Garcia-Dorado, David et al.
DOI: 10.1007/s10557-019-06889-7

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.

PMID: 30621698
Journal: BMC Medicine
Year: 2019
Reference: BMC Med. 2019 Jan 9;17(1):8. doi: 10.1186/s12916-018-1233-1.
Impact factor: 8.285
Publication type: Paper in international publication
Authors: Canes, Jordi, Gavila, Joaquin, Oliveira, Mafalda, Pascual, Tomas, Perez-Garcia, Jose, Gonzalez, Xavier, Ciruelos, Eva, Munoz, Montserrat, Virizuela, Juan A, Ruiz, Isabel et al.
DOI: 10.1186/s12916-018-1233-1

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.

PMID: 30642819
Journal: Lancet Haematology
Year: 2019
Reference: Lancet Haematol. 2019 Feb;6(2):e67-e78. doi: 10.1016/S2352-3026(18)30217-5. Epub 2019 Jan 11.
Impact factor: 11.99
Publication type: Paper in international publication
Authors: Lopez-Guillermo, Armando, Ben-Yehuda, Dina, Ferhanoglu, Burhan, Nagler, Arnon, Ozcan, Muhit, Avivi, Irit, Bosch, Francesc, Caballero Barrigon, Maria Dolores, Hellmann, Andrzej, Kuss, Bryone et al.
DOI: 10.1016/S2352-3026(18)30217-5

Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study.

PMID: 30307344
Journal: JOURNAL OF DERMATOLOGICAL TREATMENT
Year: 2019
Reference: J Dermatolog Treat. 2019 Aug;30(5):461-465. doi: 10.1080/09546634.2018.1535690. Epub 2018 Nov 28.
Impact factor: 2.112
Publication type: Paper in international publication
Authors: Carrascosa, J M, Montes-Torres, A, Aparicio, G, Rivera, R, Vilarrasa, E, Marcellan, M, Notario, J, Soria, C, Belinchon, I, de la Cueva, P et al.
DOI: 10.1080/09546634.2018.1535690

Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada.

PMID: 31159865
Journal: BMC Pharmacology & Toxicology
Year: 2019
Reference: BMC Pharmacol Toxicol. 2019 Jun 3;20(1):37. doi: 10.1186/s40360-019-0302-1.
Impact factor: 2.103
Publication type: Paper in international publication
Authors: Aznar, Maria Luisa, Mehrabi, Mahtab, Brode, Sarah K, Elshal, Ahmed Said, Marras, Theodore K et al.
DOI: 10.1186/s40360-019-0302-1

Safety and effectiveness of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) against P. aeruginosa: in vitro and in vivo studies following pulmonary and intramuscular administration.

PMID: 30849549
Journal: Nanomedicine-Nanotechnology Biology and Medicine
Year: 2019
Reference: Nanomedicine. 2019 Jun;18:101-111. doi: 10.1016/j.nano.2019.02.014. Epub 2019 Mar 6.
Impact factor: 5.57
Publication type: Paper in international publication
Authors: Aguirre, J J, Esquisabel, A, Igartua, M, Gainza, E, Hernandez, R M, Gavalda, J, Pedraz, J L, Gutierrez, F B, Bachiller, D, Fleischer, A et al.
DOI: 10.1016/j.nano.2019.02.014

Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.

PMID: 30446802
Journal: ANNALS OF HEMATOLOGY
Year: 2019
Reference: Ann Hematol. 2019 Feb;98(2):321-330. doi: 10.1007/s00277-018-3507-2. Epub 2018 Nov 16.
Impact factor: 2.85
Publication type: Paper in international publication
Authors: Claudiani, Simone, Garcia-Gutierrez, Valentin, Milojkovic, Dragana, Hernandez-Boluda, Juan Carlos, Ramirez, Maria Jose, Romero, Esperanza, Romo, Andres, Rosell, Ana, Saavedra, Silvanna Saavedra, Sebrango, Ana et al.
DOI: 10.1007/s00277-018-3507-2

Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial.

PMID: 30978502
Journal: Journal of Thoracic Oncology
Year: 2019
Reference: J Thorac Oncol. 2019 Jul;14(7):1266-1276. doi: 10.1016/j.jtho.2019.03.020. Epub 2019 Apr 9.
Impact factor: 12.46
Publication type: Paper in international publication
Authors: Schildhaus, Hans-Ulrich, Franklin, Jeremy, Sebastian, Martin, Felip, Enriqueta, Grohe, Christian, Rodriguez-Abreu, Delvys, Abdulla, Diana S Y, Bischoff, Helge, Brandts, Christian, Carcereny, Enric et al.
DOI: 10.1016/j.jtho.2019.03.020

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.

PMID: 30383184
Journal: JAMA Oncology
Year: 2019
Reference: JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628.
Impact factor: 22.416
Publication type: Paper in international publication
Authors: Mesia, Ricard, Siu, Lillian L, Even, Caroline, Delord, Jean-Pierre, Krauss, Jurgen, Saba, Nabil F, Nabell, Lisle, Ready, Neal E, Brana, Irene, Kotecki, Nuria et al.
DOI: 10.1001/jamaoncol.2018.4628

Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172).

PMID: 31581055
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2019
Reference: Eur J Cancer. 2019 Nov;121:144-153. doi: 10.1016/j.ejca.2019.08.014. Epub 2019 Sep 30.
Impact factor: 6.68
Publication type: Paper in international publication
Authors: Hoeller, Christoph, Schadendorf, Dirk, Ascierto, Paolo A, Haanen, John, Espinosa, Enrique, Demidov, Lev, Garbe, Claus, Guida, Michele, Lorigan, Paul, Chiarion-Sileni, Vanna et al.
DOI: 10.1016/j.ejca.2019.08.014

Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172).

PMID: 31445199
Journal: EUROPEAN JOURNAL OF CANCER
Year: 2019
Reference: Eur J Cancer. 2019 Sep;119:168-178. doi: 10.1016/j.ejca.2019.07.010. Epub 2019 Aug 21.
Impact factor: 6.68
Publication type: Paper in international publication
Authors: Gutzmer, Ralf, Nathan, Paul, Ascierto, Paolo A, Haanen, John, Espinosa, Enrique, Demidov, Lev, Garbe, Claus, Guida, Michele, Lorigan, Paul, Chiarion-Sileni, Vanna et al.
DOI: 10.1016/j.ejca.2019.07.010

Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.

PMID: 31487218
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2019
Reference: J Clin Oncol. 2019 Nov 1;37(31):2825-2834. doi: 10.1200/JCO.19.00739. Epub 2019 Sep 5.
Impact factor: 28.245
Publication type: Paper in international publication
Authors: Naumann, R Wendel, Hollebecque, Antoine, Meyer, Tim, Devlin, Michael-John, Oaknin, Ana, Kerger, Joseph, Lopez-Picazo, Jose M, Machiels, Jean-Pascal, Delord, Jean-Pierre, Evans, Thomas R J et al.
DOI: 10.1200/JCO.19.00739

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.

PMID: 31285147
Journal: LANCET NEUROLOGY
Year: 2019
Reference: Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5.
Impact factor: 28.755
Publication type: Paper in international publication
Authors: Rudick, Richard, Cadavid, Diego, Mellion, Michelle, Hupperts, Raymond, Edwards, Keith R, Calabresi, Peter A, Drulovic, Jelena, Giovannoni, Gavin, Hartung, Hans-Peter, Arnold, Douglas L et al.
DOI: 10.1016/S1474-4422(19)30137-1

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial.

PMID: 31492652
Journal: LANCET NEUROLOGY
Year: 2019
Reference: Lancet Neurol. 2019 Nov;18(11):1021-1033. doi: 10.1016/S1474-4422(19)30238-8. Epub 2019 Sep 3.
Impact factor: 28.755
Publication type: Paper in international publication
Authors: Cohen, Jeffrey A, Comi, Giancarlo, Selmaj, Krzysztof W, Bar-Or, Amit, Arnold, Douglas L, Steinman, Lawrence, Hartung, Hans-Peter, Montalban, Xavier, Kubala Havrdova, Eva, Cree, Bruce A C et al.
DOI: 10.1016/S1474-4422(19)30238-8

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.

PMID: 31492651
Journal: LANCET NEUROLOGY
Year: 2019
Reference: Lancet Neurol. 2019 Nov;18(11):1009-1020. doi: 10.1016/S1474-4422(19)30239-X. Epub 2019 Sep 3.
Impact factor: 28.755
Publication type: Paper in international publication
Authors: Cree, Bruce A C, Sheffield, James K, Minton, Neil, Raghupathi, Kartik, Ding, Ning, Cohen, Jeffrey A, Kubala Havrdova, Eva, Montalban, Xavier, Steinman, Lawrence, Comi, Giancarlo et al.
DOI: 10.1016/S1474-4422(19)30239-X

Publications